09:16 AM EST, 12/23/2024 (MT Newswires) -- Wave Life Sciences ( WVE ) said Monday it has filed its first clinical trial application for WVE-007 to treat obesity.

The company said it expects approval of the clinical trial application and the start of the first-in-human trial of WVE-007 in Q1 2025.

WVE-007 is a new approach to treat obesity that was designed to reach "healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twice-annual dosing," Wave said.